N/A N=512 My Diabetes, My Community
Type 2 Diabetes
Primary: Mean Change in Percent of Hemoglobin A1C — -1.1; -0.8; -0.8 percentage of hemoglobin A1C — p=0.8
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 4 N=10 Fenofibrate in Type 2 Diabetes
Diabetes Mellitus, Type II
Primary: Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid…
Phase 3 N=1,791 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Type 2 Diabetes Mellitus
Primary: Primary Major Macrovascular Events — 264; 235 participants — p=<0.05
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 4 N=150 Diabetes in the Elderly: Prospective Study
Diabetes · Hyperglycemia
Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL — 28; 31 percentage of participants
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
Phase 4 N=14 Depression-Diabetes Mechanisms: Urban African Americans
Diabetes · Depression
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24 — 2; 1; 2; 1 participants
N/A N=42 Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes
Type 2 Diabetes · Oxidative Stress
Primary: Concentration of Vitamin C in Type 2 Diabetic Patients. — 1.1; 1.2 umol/g tissue
Phase 4 N=318 Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Diabetes
Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin
N/A N=102 Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes
Coronary Heart Disease · Stroke · Renal Failure
Primary: Cardiovascular Mortality — 7; 11 participants — p=0.30
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
N/A N=120 Diabetes Education With Real-time Continuous Glucose Monitoring
Diabetes Type 2
Primary: Hemoglobin A1C — -2.3; -1.5 percent change in A1C
N/A N=57 Estrogen and Diabetes
Diabetes Mellitus, Type 1
Primary: FMD/Shear — 0.182; 0.206; 0.155; 0.219 %/s^-1
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=11 Hypoglycemia (Low Blood Sugar) and the Heart
Hypoglycemia · Type 2 Diabetes
Primary: Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl — 11 Participants
N/A N=187 Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 Diabetes Mellitus · Colonoscopy
Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants
Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)
N/A N=32 Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus
Diabetes
Primary: Radiographic Bone Level — 2.69; 2.54 mm
N/A N=1,274 Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
Corneal Endothelial Decompensation · Fuchs' Endothelial Dystrophy
Primary: Graft Failure — 32; 15 eyes
N/A N=90 Exercise Training and Glucose Metabolism in Aging
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance (Prediabetes)
Primary: Baseline Glucose Utilization — 0.0062; 0.0035 µmol/kgFFM/pmol insulin/min
N/A N=169 An Educational Intervention for Type 2 Diabetes Patients
Diabetes Mellitus
Primary: Patients' Perceived Self-efficacy to Communicate — 22.11; 22.14; 23.44; 22.63 units on a scale
N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Phase 3 N=3,472 Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Diabetic Retinopathy
Primary: Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of…
N/A N=28 Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes
Diabetes Type 2
Primary: Diff AUC SS0.5 Hyperglycemic — 0.74; 0.96 Pa*hr
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
N/A N=80 Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease
Diabetes · Kidney Diseases
Primary: Mean Glucose Concentration Measured by CGM — 151.5 mg/dL